Expert Point of View: Shridar Ganesan, MD, PhD


Get Permission

Shridar Ganesan, MD, PhD

Shridar Ganesan, MD, PhD

Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discussed the study on the gut microbiome. Dr. Ganesan noted that response to immunotherapy depends not only on tumor characteristics, but on the immune ­microenvironment as well, and this can clearly be influenced by host factors. These data suggest “that what’s happening in the gut may also reflect, in part, what kind of response occurs in the tumor,” he indicated.

Manipulation of intestinal flora affects the efficacy of checkpoint blockade in mouse tumor models, noted Dr. Ganesan, and gut microbiome profiles correlate with the development of colitis in patients treated with the checkpoint inhibitor ipilimumab (Yervoy).

Developing Biomarkers

As more information emerges about the microbiome’s importance, Dr. Ganesan said, a key consideration will be how to integrate host features (microbiome, other markers) with tumor features in developing biomarkers of response and resistance. ■

Disclosure: Dr. Ganesan reported relationships with Inspirata, Novartis, and Merck.


Related Articles

Gut Bacteria May Enhance, or Hamper, Response to Anti–PD-1 Agents

The microbiome has become an area of intense interest for many health-related reasons. Add to this list the potential for a positive or a negative effect on responsiveness to immunotherapy. Gut microbiota that were more diverse, and that contained an abundance of a particular bacterial species,...


Advertisement

Advertisement



Advertisement